Regencell Bioscience Holdings Limited
RGC
NASDAQ
Healthcare
$6.37
-20.67%loss today
Market position
Market cap rank
#1755
of 2,614
1-day
-20.67%
1-month
-72.48%
6-month
-69.67%
YTD
-68.99%
1-year
-38.51%
5-year
+2,205.30%
Key figures
Market cap
$3.15B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-2366.7
FY 2025
EPS
-$0.0072
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$8.42B
FY 2025
EV / EBITDA
-2639.60
FY 2025
EV / Sales
0.00
FY 2025
Price / book
1733.67
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-0.04%
FY 2025
FCF yield
-0.04%
FY 2025
Debt / equity
0.11
FY 2025
Current ratio
7.39
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-392.74K
Operating income
$-3.77M
EBITDA
$-3.19M
Net income
$-3.58M
Diluted EPS
-$0.0072
Shares outstanding
494,488,908
Trading
Open
$8.09
Previous close
$8.03
Day range
$6.32 – $8.17
52-week range
$5.80 – $69.00
50-day avg
$21.73
200-day avg
$22.19
Volume
916,622
Avg volume
199,877
Beta
1.83
Price history
-38.51% over 1Y
Compare with peers
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Visit websiteCompany info
CEO
Yat-Gai Au
IPO date
Jul 16, 2021
Headquarters
Causeway Bay, HK
Country
HK
Fundamentals are annual. Figures labeled with their fiscal year.
